Nuvalent Inc
NUVL92.090USD
+1.070+1.18%
收盤 11/05, 16:00（美東）報價延遲15分鐘
6.66B總市值
虧損本益比TTM
關於 Nuvalent Inc 公司
Nuvalent, Inc. 是一家臨牀階段的生物製藥公司，專注於爲臨牀驗證的癌症激酶靶點開發精準靶向療法。該公司開發的小分子具有克服耐藥性、最大程度減少不良事件、解決腦轉移和推動更持久反應的潛力。該公司正在推進強大的產品線，其中包括針對 ROS1 陽性、ALK 陽性和 HER2 陽性非小細胞肺癌的在研候選藥物以及多個發現階段的研究項目。其候選產品 NVL-520 正在爲 ROS 原癌基因 1 (ROS1) 陽性非小細胞肺癌 (NSCLC) 患者開發。NVL-520 是一種新型 ROS1 選擇性抑制劑。其候選產品 NVL-655 正在爲間變性淋巴瘤激酶 (ALK) 陽性 NSCLC 患者開發。LC。NVL-655 是一種腦滲透性 ALK 選擇性抑制劑。其候選產品 NVL-330 是一種腦滲透性人表皮生長因子受體 2 (HER2) 選擇性抑制劑。
Nuvalent Inc簡介
公司代碼NUVL
公司名稱Nuvalent Inc
上市日期Jul 29, 2021
CEODr. James R. (Jim) Porter, Ph.D.
員工數量142
證券類型Ordinary Share
年結日Jul 29
公司地址One Broadway, 14Th Floor
城市CAMBRIDGE
上市交易所NASDAQ Global Select Consolidated
國家United States of America
郵編02142
電話18573577000
網址https://www.nuvalent.com/
公司代碼NUVL
上市日期Jul 29, 2021
CEODr. James R. (Jim) Porter, Ph.D.
Nuvalent Inc公司高管
名稱
名稱/職務
職務
持股
持股變動
Dr. Matthew Shair, Ph.D.
Dr. Matthew Shair, Ph.D.
Director, Scientific Founder, Head Scientific Advisor
Director, Scientific Founder, Head Scientific Advisor
1.60M
-2.85%
Dr. Henry E. Pelish, Ph.D.
Dr. Henry E. Pelish, Ph.D.
Chief Scientific Officer
Chief Scientific Officer
65.96K
--
Ms. Alexandra (Alex) Balcom, CPA
Ms. Alexandra (Alex) Balcom, CPA
Chief Financial Officer, Treasurer
Chief Financial Officer, Treasurer
20.78K
--
Ms. Darlene Noci
Ms. Darlene Noci
Chief Development Officer
Chief Development Officer
7.08K
--
Dr. Joseph Pearlberg, M.D., Ph.D.
Dr. Joseph Pearlberg, M.D., Ph.D.
Non-Executive Independent Director
Non-Executive Independent Director
5.15K
+105.92%
Ms. Christy J. Oliger
Ms. Christy J. Oliger
Independent Director
Independent Director
3.97K
--
Dr. Michael L. Meyers, M.D., Ph.D.
Dr. Michael L. Meyers, M.D., Ph.D.
Non-Executive Independent Director
Non-Executive Independent Director
2.65K
--
Dr. Sapna Srivastava, Ph.D.
Dr. Sapna Srivastava, Ph.D.
Non-Executive Independent Director
Non-Executive Independent Director
2.65K
--
Dr. Christopher D. Turner, M.D.
Dr. Christopher D. Turner, M.D.
Chief Medical Officer
Chief Medical Officer
--
--
Dr. James R. (Jim) Porter, Ph.D.
Dr. James R. (Jim) Porter, Ph.D.
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
--
--
查看更多
名稱
名稱/職務
職務
持股
持股變動
Dr. Matthew Shair, Ph.D.
Dr. Matthew Shair, Ph.D.
Director, Scientific Founder, Head Scientific Advisor
Director, Scientific Founder, Head Scientific Advisor
1.60M
-2.85%
Dr. Henry E. Pelish, Ph.D.
Dr. Henry E. Pelish, Ph.D.
Chief Scientific Officer
Chief Scientific Officer
65.96K
--
Ms. Alexandra (Alex) Balcom, CPA
Ms. Alexandra (Alex) Balcom, CPA
Chief Financial Officer, Treasurer
Chief Financial Officer, Treasurer
20.78K
--
Ms. Darlene Noci
Ms. Darlene Noci
Chief Development Officer
Chief Development Officer
7.08K
--
Dr. Joseph Pearlberg, M.D., Ph.D.
Dr. Joseph Pearlberg, M.D., Ph.D.
Non-Executive Independent Director
Non-Executive Independent Director
5.15K
+105.92%
Ms. Christy J. Oliger
Ms. Christy J. Oliger
Independent Director
Independent Director
3.97K
--
收入明細
暫無數據
暫無數據
業務
地區
暫無數據
股東統計
更新時間: 8月15日 週五
更新時間: 8月15日 週五
持股股東
股東類型
持股股東
持股股東
佔比
Deerfield Management Company, L.P.
26.74%
Fidelity Management & Research Company LLC
14.47%
Paradigm BioCapital Advisors LP
7.83%
The Vanguard Group, Inc.
6.71%
BlackRock Institutional Trust Company, N.A.
4.52%
其他
39.73%
持股股東
持股股東
佔比
Deerfield Management Company, L.P.
26.74%
Fidelity Management & Research Company LLC
14.47%
Paradigm BioCapital Advisors LP
7.83%
The Vanguard Group, Inc.
6.71%
BlackRock Institutional Trust Company, N.A.
4.52%
其他
39.73%
股東類型
持股股東
佔比
Hedge Fund
45.15%
Investment Advisor
39.34%
Investment Advisor/Hedge Fund
19.04%
Individual Investor
2.77%
Private Equity
2.04%
Research Firm
1.73%
Sovereign Wealth Fund
0.56%
Pension Fund
0.26%
Bank and Trust
0.24%
機構持股
更新時間: 10月1日 週三
更新時間: 10月1日 週三
報告期間
機構數
持股數
持股佔比
持股變動
2025Q3
437
72.94M
108.44%
-3.70M
2025Q2
438
75.09M
113.13%
-1.35M
2025Q1
443
75.23M
113.38%
-1.51M
2024Q4
428
73.56M
111.20%
-2.43M
2024Q3
401
72.99M
113.51%
-264.12K
2024Q2
367
68.27M
114.85%
-2.37M
2024Q1
344
66.52M
113.46%
-4.79M
2023Q4
296
66.77M
116.76%
+1.56M
2023Q3
249
58.89M
114.16%
-3.80M
2023Q2
230
58.54M
113.63%
-2.82M
查看更多
股東持股明細
名稱
持股數
佔比
持股變動
變動比例
公告日期
Deerfield Management Company, L.P.
17.99M
26.99%
--
--
Jun 30, 2025
Fidelity Management & Research Company LLC
9.73M
14.6%
+31.95K
+0.33%
Jun 30, 2025
Paradigm BioCapital Advisors LP
5.27M
7.9%
--
--
Jun 30, 2025
The Vanguard Group, Inc.
4.52M
6.77%
+83.60K
+1.89%
Jun 30, 2025
BlackRock Institutional Trust Company, N.A.
3.04M
4.56%
+310.84K
+11.39%
Jun 30, 2025
Janus Henderson Investors
1.78M
2.67%
+472.38K
+36.05%
Jun 30, 2025
T. Rowe Price Associates, Inc.
1.76M
2.63%
+338.01K
+23.83%
Jun 30, 2025
Shair (Matthew)
1.64M
2.47%
+2.65K
+0.16%
Jun 18, 2025
Wellington Management Company, LLP
1.58M
2.36%
+133.99K
+9.29%
Jun 30, 2025
State Street Investment Management (US)
1.49M
2.24%
+59.62K
+4.17%
Jun 30, 2025
查看更多
持股ETF
更新時間: 11月2日 週日
更新時間: 11月2日 週日
機構名稱
佔比
Tema Oncology ETF
4.06%
ALPS Medical Breakthroughs ETF
3.3%
Global X Guru Index ETF
1.4%
SPDR S&P Biotech ETF
1.07%
Virtus LifeSci Biotech Clinical Trials ETF
0.8%
Direxion Daily S&P Biotech Bull 3X Shares
0.61%
ProShares Ultra Nasdaq Biotechnology
0.6%
Invesco Nasdaq Biotechnology ETF
0.58%
iShares Health Innovation Active ETF
0.58%
iShares Biotechnology ETF
0.37%
查看更多
Tema Oncology ETF
佔比4.06%
ALPS Medical Breakthroughs ETF
佔比3.3%
Global X Guru Index ETF
佔比1.4%
SPDR S&P Biotech ETF
佔比1.07%
Virtus LifeSci Biotech Clinical Trials ETF
佔比0.8%
Direxion Daily S&P Biotech Bull 3X Shares
佔比0.61%
ProShares Ultra Nasdaq Biotechnology
佔比0.6%
Invesco Nasdaq Biotechnology ETF
佔比0.58%
iShares Health Innovation Active ETF
佔比0.58%
iShares Biotechnology ETF
佔比0.37%
分紅派息
近5年累計派現
0.00
美元
公告日期
分紅計劃
股權登記日
現金發放日
除權除息日
暫無數據
拆合股
公告日期
類型
比率
暫無數據
公告日期
類型
比率
暫無數據
